Delivery Order SPE2DB22D3019-SPE2DB25FK4BJ
- Not listed
- The Defense Logistics Agency awarded a $3,998.11 delivery order to AmerisourceBergen Drug Corp for Mestinon 180 mg Timespan in quantities of 30 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation, featuring an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its Corporate Office location in Conshohocken, PA 19428. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.36 to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed-price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Mestinon is a pharmaceutical product used in the treatment of myasthenia gravis and related...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,667.30 by the Defense Logistics Agency's Medical Supply Chain on August 8, 2025, for the supply of Mestinon 180 mg Timespan in units of 30 tablets. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025....
- The Defense Logistics Agency awarded a delivery order valued at $16,164.41 to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This competitive delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price transaction with no set-aside designation. The product will be performed and delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania, supporting federal medical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,963.15 firm-fixed-price contract is for the supply of Mestinon 180 mg Timespan medication. This delivery order falls under a larger Indefinite Delivery Contract with the DLA Troop Support Medical valued up to $999,999,999 through December 2025, which provides a wide range of pharmaceutical and medical supplies to military treatment facilities and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product, with a ceiling value of $11,065.59 and a period of performance ending on May 29, 2025. The contract is a firm-fixed-price delivery order and is not a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp is...
- This federal contract award is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The contract is for the supply of MESTINON 180 MG TIMESPAN UU 30S, a prescription medication, with a ceiling value of $2,245.38. The contract is a Firm Fixed Price arrangement and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award is a $6,196.15 firm fixed-price delivery order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product. The contract has an ultimate completion date of May 14, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,235.88, is for the supply of 180 mg Mestinon Timespan medication. The contract is a firm fixed-price delivery order with a completion date of March 27, 2025. There is no set-aside designation for this award. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MESTINON 180 MG TIMESPAN UU 30S medication. The contract has a firm fixed price of $5,440.14 and a completion date of May 21, 2024. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK4BJDelivery Order
The Defense Logistics Agency awarded a $5,900.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 11, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. Mestinon (pyridostigmine bromide) is a medication used in the treatment of myasthenia gravis and other neuromuscular conditions. The company's federal contracting history demonstrates consistent capability to fulfill open competition requirements across diverse pharmaceutical product categories and delivery scales, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through its flexible and comprehensive contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 8/8/25 |